Intracavernosal injection and intraurethral therapy for erectile dysfunction

Urologic Clinics of North America

Volumn 28, Issue 2, 2001, Pages 343-354

  Leungwattanakij, Somboon ^b   Flynn Jr, Vincent ^b   Hellstrom, Wayne J G ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALIBRA; BICARBONATE; FORSKOLIN; GLYCERYL TRINITRATE; LIDOCAINE; LIMAPROST; LINSIDOMINE; MINOXIDIL; PAPAVERINE; PHENTOLAMINE; PHENYLEPHRINE; POTASSIUM CHANNEL STIMULATING AGENT; PRAZOSIN; PROCAINE; PROSTAGLANDIN E1; SILDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE; YOHIMBINE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; ERECTILE DYSFUNCTION; FIBROSIS; HUMAN; HYPOTENSION; PAIN; PRIAPISM; PRIORITY JOURNAL; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; URINARY TRACT INFECTION; VERTIGO;

EID: 0034987189     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70143-9     Document Type: Article

References (81)

1. Cholinoreceptors in the corpus cavernosum of the human penis
2. An improved vasoactive drug combination for a pharmocological erection program
3. Induction of penile erection by intracavernosal and transurethral administration of zaprinast and PGE-1
4. Intraurethral alprostadil for treatment of erectile dysfunction in patients with spinal cord injury
5. A new approach to the pharmacologic treatment of impotence
6. Biosynthesis of nitric oxide and citrulline from L-arginine by constitutive nitric oxide synthase present in rabbit corpus cavernosum
7. Intracavernous injection of papaverine: Assessment of its diagnostic and therapeutic value in 100 impotent patients
8. Forskolin: A promising new adjunct to intracavernous pharmacotheraphy
9. Transdermal therapy of erectile insufficiency
10. Minoxidil versus nitroglycerine: A prospective double-blind, controlled trial in transcutaneous erectile facilitation for organic impotence
11. Minoxidil versus nitroglycerin: A prospective double-blind, controlled trial in transcutaneous erectile therapy for organic impotence
12. Pharmacokinetics of PGE 1 and its main metabolites after intracavernous injection and short-term infusion of PGE 1 in patients with erectile dysfunction
13. Induction of penile erection by intracavernosal and transurethral administration of novel nitric oxide donors in the cat
14. Transcutaneous nitroglycerine therapy in the treatment of impotence
15. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy
16. Oral, transdermal and transurethral therapies
17. Involvement of the sympathetic nervous system in the urinary bladder internal sphincter and in penile erection in the anesthetized cat
18. Disappointing initial results with the transurethral alprostadil for erectile dysfunction in a urology practice setting
19. Treatment of erectile failure with prostaglandin E1: A double-blind, placebo-controlled, dose-response study
20. Transcutaneous nitroglycerine in the treatment of erectile dysfunction: A placebo controlled clinical trial
21. Fate of prostaglandins E1 and A1 in the pulmonary circulation
22. A double-blind, placebo controlled evaluation of the erectile response to transurethral alprostadil
23. Effects of alprostadil and prazosin on motility, viability and membrane integrity of human sperm
24. K(+)-channel openers for relaxation of isolated penile erectile tissue from rabbit
25. Intracavernous injection of PGE 1 for the treatment of erectile impotence
26. Pharmacotherapy of erectile dysfunction: A review
27. Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with a combination of prostaglandin E1 and lidocaine in the treatment of organic impotence
28. Double-blind trial of oral PGE 1 on impotence
29. Topical PGE 1 for the treatment of erectile dysfunction
30. Papaverine topical gel for treatment of erectile dysfunction
31. Safety and efficacy evaluation of transurethral alprostadil (MUSE) in Thai men with erectile dysfunction, multi-center, open-labeled study
32. Transurethral alprostadil for the treatment of erectile dysfunction: Two-year safety update
33. Intracavernous injection therapy: Analysis of results and complications
34. Intraurethral infused capsaicin induces penile erection in humans
35. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence
36. Combined use of transurethral alprostadil and an adjustable penile constriction band in men with erectile dysfunction: Results from a multicenter trial
37. Combined use of transurethral alprostadil and an adjustable penile constriction band in men with erectile dysfunction: Results from a multicenter trial
38. Risk factors for papaverine-induced priapism
39. Priapism: A refined approach to diagnosis and treatment
40. Impotence
41. A comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, prostaglandin E1, and a combination of all three agents in the management of impotence
42. Topical PGE 1 SEPA gel for the treatment of erectile dysfunction
43. The epidemiology and pathophysiology of erectile dysfunction
44. A KATP-channel opener as a potential treatment modality for erectile dysfunction
45. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction
46. Intracavernosal forskolin: Role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy
47. Effectiveness of combination therapy of MUSE and Viagra in the salvage of erectile dysfunction patients desiring noninvasive therapy
48. Topical nitroglycerine therapy in the treatment of impotence
49. Corporal pharmacotherapy for erectile dysfunction and priapism
50. Multicenter double-blind, placebo-controlled trial of transurethral alprostadil in men with chronic erectile dysfunction
51. Treatment of erectile dysfunction by the medicated urethral system for erection (MUSE)
52. Intracavernosal pharmacotherapy: The pharmacologic erection program
53. Medicated Urethral System for Erection (MUSE) Study Group: Treatment of men with erectile dysfunction with transurethral alprostadil
54. Hemodynamic effects of intraurethral alprostadil: The Medicated Urethral System for Erection (MUSE)
55. Transurethral alprostadil treatment of erectile dysfunction: Clinical and pharmacokinetic correlations
56. Improved erectile response to transurethral alprostadil by use of a novel, adjustable penile band
57. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations
58. The medicated urethral system for erection: Does transurethral alprostadil affect the concentration of prostaglandins in human ejaculate or the viability and motility of human sperm
59. Prostaglandin E1 bei erektiler dysfunktion
60. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience
61. Differential in vivo pulmonary degradation of PGE1, B1 and A1
62. Intracorporal injection of papaverine and phentolamine in the management of impotence
63. Metabolic disposition of PGE 1 in man
64. Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection
65. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection
66. A prospective comparative study of the safety and efficacy of sildenafil citrate in a group of men previously randomized to intraurethral vs intracavernosal PGE 1
67. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction
68. Intracavernous injection of PGE 1 plus procaine in the treatment of erectile dysfunction
69. Clinical experience with vasoactive intracavernous pharmacotherapy for treatment of impotence
70. The ultrastructure of penile erection in priapism
71. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction
72. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction
73. Functional and radiologic evidence of vascular communication between the spongiosal and cavernosal compartments of the penis
74. Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure
75. Efficacy and side effects of PGE 1 in the treatment of erectile dysfunction
76. Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction
77. MUSE therapy: Preliminary clinical observations
78. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction
79. Intraurethral PGE 2: A possible alternative treatment for erectile dysfunction
80. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence